The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

polyprox.com

Founded Year

2019

Stage

Seed | Alive

Total Raised

$5.71M

Last Raised

$1.28M | 2 yrs ago

About PolyProx Therapeutics

PolyProx Therapeutics develops Polyproxin molecules, a class of drugs that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.

PolyProx Therapeutics Headquarter Location

Jonas Webb Building (B910), Babraham Research Campus

Cambridge, England, CB22 3AT,

United Kingdom

+44 (0)1223 804 420

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PolyProx Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PolyProx Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest PolyProx Therapeutics News

PolyProx Therapeutics Raises an Additional £1 Million Seed Financing From New Investor LifeArc to Validate Polyproxin Drug Leads in Oncology

Mar 2, 2020

The additional funding will be used to deliver in vivo proof of concept data for polyproxin® molecule leads against two oncology drug targets. This data will form the basis for Series A financing in 2021. PolyProx Therapeutics is developing polyproxin® molecules that target and remove disease-causing proteins using the natural degradation machineries contained within the cell. Its initial focus is to develop polyproxin® molecule candidates for use in the treatment of cancers, targeting aberrant proteins that have previously proven difficult to target using conventional drug classes, such as small molecules or monoclonal antibodies. A spin out from the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from Founder Professor Laura Itzhaki’s laboratory. Serial Cambridge biotech entrepreneurs Kevin Moulder (Chief Operating Officer) and Andrew Sandham (Executive Chairman), lead the team. Independent medical research charity, LifeArc, is focused on translation; helping to turn promising science into benefits for patients by advancing medical research towards patient treatments and diagnostics. LifeArc’s investment in PolyProx Therapeutics has been made via the LifeArc Seed Fund, a £25 million fund focused predominantly on opportunities in the UK with the objective of optimising the chances of bringing transformative science to the clinic. Enrique Millan, Investment Principal, LifeArc Seed Fund, who will sit on the PolyProx Therapeutics board commented: “LifeArc’s Seed Fund was established to help translate promising medical research into patient benefit. We are excited to be working with the PolyProx team on the development of a novel, first-in-class therapeutic modality that could potentially address some of the challenges in cancer treatment.” Andrew Sandham, Executive Chairman, PolyProx Therapeutics added: “We are delighted to welcome LifeArc as an investor which enables us to expand our drug discovery resources following our recent move to new laboratories in Cambridge. We have made exciting progress on our polyproxin® drug discovery projects in oncology and look forward to sharing proof of concept data with prospective investors and partners later this year.” For more information please visit: www.polyprox.com - Ends - Limewash, PR Agency

  • When was PolyProx Therapeutics founded?

    PolyProx Therapeutics was founded in 2019.

  • Where is PolyProx Therapeutics's headquarters?

    PolyProx Therapeutics's headquarters is located at Jonas Webb Building (B910), Babraham Research Campus, Cambridge.

  • What is PolyProx Therapeutics's latest funding round?

    PolyProx Therapeutics's latest funding round is Seed.

  • How much did PolyProx Therapeutics raise?

    PolyProx Therapeutics raised a total of $5.71M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.